Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioVersys AG ( (CH:BIOV) ) has shared an announcement.
BioVersys AG has received orphan designation from the European Medicines Agency for its combination of alpibectir and ethionamide for treating tuberculosis, a significant step in addressing drug resistance. This designation, following a successful Phase 2a trial and collaboration with GSK, provides incentives like market exclusivity and reduced fees, potentially enhancing treatment options for tuberculosis patients and reinforcing BioVersys’s position in the pharmaceutical industry.
The most recent analyst rating on (CH:BIOV) stock is a Buy with a CHF62.00 price target. To see the full list of analyst forecasts on BioVersys AG stock, see the CH:BIOV Stock Forecast page.
More about BioVersys AG
BioVersys AG is a clinical stage biopharmaceutical company based in Basel, Switzerland, specializing in the development of novel antibacterial products targeting serious infections caused by multidrug-resistant bacteria. The company leverages its internal technology platforms to create treatments that address unmet medical needs in antimicrobial and microbiome fields, with advanced programs focusing on nosocomial infections and tuberculosis.
Average Trading Volume: 2,037
Technical Sentiment Signal: Strong Sell
Learn more about BIOV stock on TipRanks’ Stock Analysis page.